Add like
Add dislike
Add to saved papers

Picarbutrazox effectiveness added to a seed treatment mixture for management of Oomycetes that impact soybean in Ohio.

Plant Disease 2024 January 9
None of the current oomycota fungicides are effective towards all species of Phytophthora , Phytopythium , Globisporangium , and Pythium that affect soybean seed and seedlings in Ohio. Picarbutrazox is a new oomyceticide with a novel mode of action towards Oomycete pathogens. Our objectives were to evaluate picarbutrazox to determine i) baseline sensitivity (EC50 ) to 189 isolates of 29 species, ii) the efficacy with a base seed treatment with three cultivars with different levels of resistance in 14 field environments; and iii) if the rhizosphere microbiome was affected by the addition of the seed treatment on a moderately susceptible cultivar. The mycelial growth of all isolates was inhibited beginning at 0.001µg and the EC50 ranged from 0.0013 to 0.0483 µg a.i. ml-1 . The effect of seed treatment was significantly different for plant population and yield in 8 of 14 and 6 of 12 environments, respectively. The addition of picarbutrazox at 1 and 2.5 g a.i. 100 kg seed-1 to the base seed treatment compared to the base alone was associated with higher plant populations and yield in 3 and 1 environment, respectively. There was limited impact of the seed treatment mefenoxam 7.5 g a.i. plus picarbutrazox 1 g a.i. per 100 kg seed-1 on the oomycetes detected in the rhizosphere of soybean seedlings collected at the V1 growth stage. Picarbutrazox has efficacy towards a wider range of oomycetes that cause disease on soybean and this will be another oomyceticide tool to combat early season damping-off in areas where environmental conditions highly favor disease development.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app